The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Yes, it seems likely milktrayman69.
Agreed Milkmantray69
pretty sure they will outsource this to a digital agency , hence raising of the funds as well
Marketing is very difficult because you need lot of resources e.g. funds and expertise which is very expensive and I am sure they have no other choice to take this bitter pill in the absence of taking on board of any reputable Pharma! All we can hope good luck and it will be success so every body makes bit of money who have bought at the peak.
so it does seem that they will be launching in a number of regions in the EU, in contrast to their CSD500 pilot launch in the past
Ref :manufacturing themselves , I thought that was the case last week , but that has been clarified in this interview to not be the case, they will be using a contract supplier, but need to make some capex towards it , correct me if i am wrong but he seemed to elude to the packaging side of things. Nonetheless, it seems that they are starting to ramp things there ends with a non committal timeline for commercial deals disclosure, but at least this year , using the phrase" getting deals over the line " is all positive language for me for a launch in the next few months in a NUMBER of regions, with also a concerted universal marketing campaign to deliver the same message across various geographies
My guess for the contract manufacturer would be the VLG in Italy, let’s see.
Sorry I was meant below to contract manufacturer to manufacture MED 3000.
So it means there will be no Pharma on board so they have to do marketing and an arrange distributors as well.
Please correct me if I am wrong because listening to the interview , I get the impression that are setting up MED 3000 manufacturing themselves .
thanks for the link Antropica. interesting to hear that fum intends to place emphasis on royalties rather than upfront payments. the raise make good sense in that context. indicates confidence in potential sales. quite an illuminating interview in some ways.
See link to proactive investors interview this evening.
https://www.proactiveinvestors.co.uk/companies/news/949672/futura-medicals-ceo-discusses-12m-fundraising-for-med3000-949672.html
They seem to have everything pretty much on track but I believe they have to be cautious about statements and non disclosure undertakings with commercial partners.
I am not familiar with past performance of the stock, but the reaction after the fundraising has been very encouraging. Should the FDA approval come the impact on the SP could likely be much larger as US market exposure w
would attract interest of both investors and worldwide pharma. I guess any pharma operating worldwide would condition commercial deals to obtaining both FDA approval and CE marking to maximize the market share unless FUM de-risks it further by bringing it to preproduction stage or scale it up via contractor manufacturing, which seem to be the case now they have got funded.
I got a few shares out of a whim in February (my first UK investment , the over the counter ED treatment seemed a no brainer to me) and then the CE marking recommendation came along and sold them near their peak, then got back 1/6 of the capital at 50p as the SP climbed last week and I am looking forward to reinvest by tranches as the SP takes ups and downs so I am full in for the FDA approval.
Looking at the potential market and to the fact that the medical device spec places them ahead of many competitors, I see potential for the SP to go over £2 upon FDA approval and providing all goes well and commercialisation is de-risked further any positive commercial output would secure a solid market share and support further SP growth.